Trial
NCT02065869
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Bellicum Pharmaceuticals
Collaborators
—
Condition
Acute Lymphoblastic Leukemia
Intervention
BPX-501 T cells
Why stopped
Sponsor decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-09-29